Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - tacrolimus, quantity: 3 mg - capsule - excipient ingredients: hypromellose; ethylcellulose; lactose monohydrate; magnesium stearate; titanium dioxide; iron oxide yellow; iron oxide red; gelatin; sodium lauryl sulfate; hyprolose; butan-1-ol; purified water; industrial methylated spirit; simethicone; lecithin; ethanol; shellac; strong ammonia solution; sulfuric acid - indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

Israel - English - Ministry of Health

astellas pharma international b.v., israel - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 100 mg - bendamustine - first-line of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotheraphy is not appropiate. indolent non-hodgkin’s lymphomas as monotheraphy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.

Israel - English - Ministry of Health

astellas pharma international b.v., israel - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 25 mg - bendamustine - first-line of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotheraphy is not appropiate. indolent non-hodgkin’s lymphomas as monotheraphy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.

United States - English - NLM (National Library of Medicine)

astellas pharma us, inc. - conivaptan hydrochloride (unii: 75l57r6x36) (conivaptan - unii:0nj98y462x) - vaprisol is indicated for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients. important limitation: vaprisol is not indicated for the treatment of congestive heart failure. vaprisol should only be used for the treatment of hyponatremia in patients with underlying heart failure when the expected clinical benefit of raising serum sodium outweighs the increased risk of adverse events for heart failure patients. (see precautions and adverse reactions ) vaprisol is contraindicated in patients with hypovolemic hyponatremia. the coadministration of vaprisol with potent cyp3a4 inhibitors, such as ketoconazole, itraconazole, clarithromycin, ritonavir, and indinavir, is contraindicated. (see precautions: drug interactions for details and other important considerations) vaprisol (conivaptan hydrochloride injection) premixed in 5% dextrose solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products. vaprisol does not have known potential for

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - gilteritinib fumarate, quantity: 44.2 mg - tablet, film coated - excipient ingredients: hyprolose; magnesium stearate; mannitol; titanium dioxide; macrogol 8000; hypromellose; purified talc; iron oxide yellow - xospata is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (aml) with a flt3 mutation.

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - enfortumab vedotin, quantity: 30 mg - injection, powder for - excipient ingredients: polysorbate 20; histidine hydrochloride monohydrate; histidine; trehalose dihydrate - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand-1 inhibitor.

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - enfortumab vedotin, quantity: 20 mg - injection, powder for - excipient ingredients: polysorbate 20; trehalose dihydrate; histidine; histidine hydrochloride monohydrate - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand-1 inhibitor.

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

astellas pharma europe b.v., netherlands - gilteritinib - film-coated tablet - 40 mg

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

astellas pharma malaysia sdn bhd - tacrolimus -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

astellas pharma malaysia sdn bhd - tacrolimus -